Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy

ESMO Open - Tập 1 - Trang e000118 - 2016
Christian Manegold1, Alex Adjei2, Federico Bussolino3, Federico Cappuzzo4, Lucio Crino5, Rafal Dziadziuszko6, David Ettinger7, Dean Fennell8, Keith Kerr9, Thierry Le Chevalier10, Natasha Leighl11, Mauro Papotti12, Luis Paz-Ares13, Maurice Pérol14, Solange Peters15, Robert Pirker16, Elisabeth Quoix17, Martin Reck18, Egbert Smit19,20, Everett Vokes21
1Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany
2Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA
3Department of Oncology, University of Turin, Turin and Candiolo Cancer Institute, Candiolo, Italy
4Medical Oncology Department, Istituto Toscano Tumori, Livorno, Italy
5Medical Oncology Department, Perugia University Medical School, Perugia, Italy
6Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
7Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, Baltimore, Maryland, USA
8Department of Oncology, University of Leicester & Leicester University Hospitals, Leicester, UK
9Department of Pathology, Aberdeen University Medical School, Aberdeen, UK
10Department of Medicine, Gustave Roussy University Hospital, Villejuif, France
11Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre, Toronto, Ontario, Canada
12Department of Oncology, University of Turin, Turin, Italy
13Servicio de Oncología Médica, Doce de Octubre University Hospital, Madrid, Spain
14Département de Cancérologie Médicale, Centre Léon Bérard, Lyon, France
15Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
16Department of Medicine I, Medical University of Vienna, Vienna, Austria
17Pulmonology Department, University Hospital, Strasbourg, France
18Department of Thoracic Oncology, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), Lung Clinic Grosshansdorf, Grosshansdorf, Germany
19Department of Pulmonary Diseases, VU University Medical Centre, Amsterdam, the Netherlands
20Department of Thoracic Oncology,Netherlands Cancer Institute, Amsterdam, The Netherlands
21Department of Medicine, University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA

Tài liệu tham khảo

Lortet-Tieulent, 2014, International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women, Lung Cancer, 84, 13, 10.1016/j.lungcan.2014.01.009

Peters, 2012, Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 23, vii56, 10.1093/annonc/mds226

Yang, 2005, Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003, Chest, 128, 452, 10.1378/chest.128.1.452

Janssen-Heijnen, 2003, The changing epidemiology of lung cancer in Europe, Lung Cancer, 41, 245, 10.1016/S0169-5002(03)00230-7

Schiller, 2002, Comparison of four chemotherapy regimens for advanced non–small-cell lung cancer, N Engl J Med, 346, 92, 10.1056/NEJMoa011954

Paz-Ares, 2012, Lancet Oncol, 13, 247, 10.1016/S1470-2045(12)70063-3

Fidias, 2009, Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non–small-cell lung cancer, J Clin Oncol, 27, 591, 10.1200/JCO.2008.17.1405

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: non-small cell lung cancer; Version 4.2014, 2014. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Last accessed 21 Dec 2014.

Reck, 2014, Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 25, iii27, 10.1093/annonc/mdu199

Kono, 2012, Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer, Curr Cancer Drug Targets, 12, 107, 10.2174/156800912799095144

Crinò, 2014, Therapeutic options targeting angiogenesis in non-small cell lung cancer, Eur Respir Rev, 23, 79, 10.1183/09059180.00008913

Ballas, 2011, Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC, Onco Targets Ther, 4, 43, 10.2147/OTT.S18155

Bruno, 2014, Orchestration of angiogenesis by immune cells, Front Oncol, 4, 131, 10.3389/fonc.2014.00131

Genentech. Avastin prescribing information, 2014. https://www.gene.com/download/pdf/avastin_prescribing.pdf Last accessed 21 Dec 2016.

de Boer, 2011, Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial, J Clin Oncol, 29, 1067, 10.1200/JCO.2010.29.5717

Herbst, 2010, Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial, Lancet Oncol, 11, 619, 10.1016/S1470-2045(10)70132-7

Natale, 2011, Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer, J Clin Oncol, 29, 1059, 10.1200/JCO.2010.28.5981

Ramlau, 2012, Aflibercept and docetaxel versus docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial, J Clin Oncol, 30, 3640, 10.1200/JCO.2012.42.6932

Herbst, 2011, Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial, Lancet, 377, 1846, 10.1016/S0140-6736(11)60545-X

Scagliotti, 2012, Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial, J Clin Oncol, 30, 2070, 10.1200/JCO.2011.39.2993

Heist, 2014, CALGB 30704 (Alliance): a randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer, J Thorac Oncol, 9, 214, 10.1097/JTO.0000000000000071

Teixidó, 2015, Assays for predicting and monitoring responses to lung cancer immunotherapy, Cancer Biol Med, 12, 87

Kerr, 2015, Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art?, J Thorac Oncol, 10, 985, 10.1097/JTO.0000000000000526

Hilberg, 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy, Cancer Res, 68, 4774, 10.1158/0008-5472.CAN-07-6307

Reck, 2014, Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial, Lancet Oncol, 15, 143, 10.1016/S1470-2045(13)70586-2

Hanna, 2013, Lume-Lung 2: a multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy, J Clin Oncol, 31

Reck, 2015, Tumor growth over time in patients with non-small cell lung cancer (NSCLC) of adenocarcinoma histology (ACH) treated with nintedanib and docetaxel or placebo and docetaxel: analysis of data from the LUME-Lung 1 (LL1) study, J Clin Oncol, 33, 10.1200/jco.2015.33.15_suppl.e19021

Garon, 2014, Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial, Lancet, 384, 665, 10.1016/S0140-6736(14)60845-X

Paz-Ares, 2015, Exploratory analysis of safety by histology and efficacy in a nonsquamous NSCLC subgroup in REVEL: a randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) vs DOC for second-line treatment of stage IV non-small-cell lung cancer (NSCLC), J Clin Oncol, 33, 10.1200/jco.2015.33.15_suppl.8055

Rolfo, 2014, Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?, Expert Rev Anticancer Ther, 14, 1173, 10.1586/14737140.2014.952287

Domagala-Kulawik, 2015, The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention, Transl Lung Cancer Res, 4, 177

Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med, 373, 1627, 10.1056/NEJMoa1507643

Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N Engl J Med, 373, 123, 10.1056/NEJMoa1504627

Bristol-Myers Squibb, 2015

Garon, 2015, Pembrolizumab for the treatment of non-small-cell lung cancer, N Engl J Med, 372, 2018, 10.1056/NEJMoa1501824

Soria, 2015

Merck & Co. Keytruda prescribing information, 2015. https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf Last accessed 22 Oct 2016.

Herbst, 2016, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet, 387, 1540, 10.1016/S0140-6736(15)01281-7

Roche. Press release: U.S. FDA grants Breakthrough Therapy Designation for Roche's investigational cancer immunotherapy MPDL3280A (anti-PDL1) in non-small cell lung cancer, 2015. http://www.roche.com/media/store/releases/med-cor-2015-02-02.htm Last accessed 22 Oct 2016.

Fehrenbacher, 2016, Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial, Lancet, 387, 1837, 10.1016/S0140-6736(16)00587-0

Antonia, 2016, Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study, Lancet Oncol, 17, 299, 10.1016/S1470-2045(15)00544-6

Khleif, 2013, MEDI4736, an anti-PD-L1 antibody with modified Fc domain: preclinical evaluation and early clinical results from a phase 1 study in patients with advanced solid tumors, Eur J Cancer, 49

Herbst, 2013, A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors, J Clin Oncol, 31, 10.1200/jco.2013.31.15_suppl.3000

Rizvi, 2014, Clinical trials of MPDL3280A (antiPDL1) in patients (pts) with non-small cell lung cancer (NSCLC), J Clin Oncol, 32

Kelly, 2015, Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or locally advanced solid tumors: assessment of safety and tolerability in a phase I, open-label expansion study, J Clin Oncol, 33

Gulley, 2015, Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: a phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy, J Clin Oncol, 33

Pao, 2011, New driver mutations in non-small-cell lung cancer, Lancet Oncol, 12, 175, 10.1016/S1470-2045(10)70087-5

Jubb, 2010, Biomarkers to predict the clinical efficacy of bevacizumab in cancer, Lancet Oncol, 11, 1172, 10.1016/S1470-2045(10)70232-1

Schwaederle, 2015, VEGF-A expression correlates with TP53 mutations in non-small cell lung cancer: implications for antiangiogenesis therapy, Cancer Res, 75, 1187, 10.1158/0008-5472.CAN-14-2305

Pilotto, 2014, Anti-angiogenic drugs and biomarkers in non-small-cell lung cancer: a ‘hard day's night, Curr Pharm Des, 20, 3958, 10.2174/13816128113196660757

Salgia, 2011, Prognostic significance of angiogenesis and angiogenic growth factors in non-small cell lung cancer, Cancer, 117, 3889, 10.1002/cncr.25935

Kaiser, 2013, Identification of a clinical biomarker for 2nd line combination with nintedanib in adenocarcinoma non-small cell lung cancer (NSCLC) patients in two phase III trials, Eur J Cancer, 49

Llovet, 2015, Advances in targeted therapies for hepatocellular carcinoma in the genomic era, Nat Rev Clin Oncol, 12, 408, 10.1038/nrclinonc.2015.103

Wolchok, 2014, Cancer: Antitumour immunity gets a boost, Nature, 515, 496, 10.1038/515496a

Thông tin
Thông tin xuất bản

ESMO Open

Tập 1

e000118

Thông tin tác giả